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Serum levels of retinol binding protein 
4 in women with different levels of 
adiposity and glucose tolerance
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ABSTRACT
Objective: Retinol-binding protein 4 (RBP4) is an adipokine responsible for vitamin A (retinol) 
transportation. Studies associated RBP4 increased levels with severity of type 2 diabetes mel-
litus (T2DM) and insulin resistance (IR). The study aimed to quantify RBP4 serum standards in 
women with a wide range of body mass index (BMI) and glucose tolerance level. Subjects and 
methods: Cross-sectional study was performed with 139 women divided into three groups: 
Group 1 (lean-control, n = 45) and Group 2 (obese, n = 53) with normal glucose tolerance and 
group 3 (obese with T2DM, n = 41), called G1, G2 and G3. Were assessed clinical, biochemical, 
anthropometric and body composition parameters. Results: According to data analysis, we ob-
tained in G1 higher RBP4 levels (104.8 ± 76.8 ng/mL) when compared to G2 (87.9 ± 38 ng/mL) and 
G3 (72.2 ± 15.6 ng/mL) levels. Also, were found: in G1 positive correlations of RBP4 with BMI 
(r = 0.253), glycated hemoglobin (r = 0.378) and fasting insulin (r = 0.336); in G2 with glycated 
hemoglobin (r = 0.489); in G3 with glycated hemoglobin (r = 0.330), fasting glucose (r = 0.463), 
HOMA-IR (r = 0.481). Conclusions: Although RBP4 have shown lower levels in diabetic and 
obese, a strong correlation with HOMA-IR index highlights that, in our study, there is growing 
IR when there is an increasing in RBP4 levels. Arq Bras Endocrinol Metab. 2014;58(7):709-14
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RESUMO
Objetivo: A proteína carreadora do retinol 4 (RBP4) é uma adipocina responsável pelo transpor-
te de vitamina A (retinol). Estudos associam os níveis aumentados de RBP4 com a gravidade do 
diabetes melito tipo 2 (DM2) e resistência à insulina (RI). O objetivo deste estudo foi investigar 
como esses níveis se comportam em mulheres com ampla variação do índice de massa cor-
poral (IMC) e tolerância à glicose. Sujeitos e métodos: Estudo transversal realizado com 139 
mulheres, divididas em três grupos: Grupo 1 (controles-magras; n = 45) e Grupo 2 (obesas; n = 
53), com tolerância normal à glicose; Grupo 3 (obesas DM2; n = 41), denominados G1, G2 e G3. 
Foram avaliados parâmetros clínicos, bioquímicos, antropométricos e composição corporal. 
Resultados: De acordo com a análise dos dados, obtivemos em G1 maiores níveis de RBP4 
(104,8 ± 76,8 ng/mL) em comparação ao G2 (87,9 ± 38 ng/mL) e G3 (72,2 ± 15,6 ng/mL). Também 
foram encontradas correlações positivas entre RBP4 e IMC (r = 0,253), hemoglobina glicada (r = 
0,378) e insulinemia de jejum (r = 0,336); em G2 com hemoglobina glicada (r = 0,489); G3 com 
hemoglobina glicada (r = 0,330), insulinemia de jejum (r = 0,463) e HOMA-IR (r = 0,481). Con-
clusões: Embora a RBP4 tenha apresentado níveis menores em pacientes diabéticas e obesas, 
a forte correlação com o índice HOMA-IR deixa claro que, em nosso estudo, há crescente RI 
quando os níveis dessa proteína também são crescentes. Arq Bras Endocrinol Metab. 2014;58(7):709-14
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INTRODUCTION
T he complex pathogenesis linking obesity, type 2 diabetes mellitus (T2DM), hypertension and dys-
lipidemia involve mechanisms ranging from increased 
insulin resistance (IR) through adipocytes production 
of pro-inflammatory and pro-oxidants factors. Adipo-
se tissue is the largest endocrine organ of human body 
which regulates glucose homeostasis, steroid produc-
tion, immune system action, hematopoietic and re-
productive function. Despite a strong epidemiological 
association, overweight does not explain itself T2DM 
development (1-7).
Adipokines are cytokines produced and secreted by 
adipose tissue. Many studies have suggested a central 
role of this endocrine organ predominantly in routes 
of fat storage and insulin action. Adipokines have been 
suggested as good markers of metabolic syndrome and 
unregulated production of these cytokines may change 
metabolic homeostasis, insulin sensitivity, immune res-
ponse and cardiovascular disease (8). Retinol binding 
protein 4 (RBP4) is an adipokine with recent discovery, 
reported by contributing to the IR and T2DM, belongs 
to lipocalins family and transports vitamin A (retinol) 
from liver to peripheral tissues. The protein encoder 
gene is located on chromosome 10 (10q23.33) near re-
gions encoding genes linked to increased levels of fast-
ing glucose, such as gene TCF7L2 (10q25.3) which 
controls CREB and Fox01 genes (9-12).
Liver is responsible for major seric output of RBP4, 
followed by adipose tissue which expresses 20% to 40% 
of liver expression. The exact physiological function of 
adipocyte-derived RBP4 is unclear. A recent study has 
shown that vitamin A and its metabolites regulate adi-
pogenesis. RBP4 production is elevated in animal mo-
dels with severe IR (GLUT4 knockout only in adipose 
tissue), resulting in up-regulation of RBP4 expression 
and hyperglycemia by the interference of insulin signal-
ing (13-15).
RBP4 serum levels are elevated in subjects with im-
paired glucose tolerance, T2DM and inversely correla-
ted with insulin sensitivity in non-diabetic subjects with 
familial history of T2DM. RBP4 levels correlate with 
degree of IR in those subjects, and this relation is in-
dependent of obesity (16-25). In addition to lower in-
sulin sensitivity, a negative effect on secretion of β-cells 
caused by RBP4 is suggested. On the other hand, there 
is a variety of recent studies that did not find in RBP4 
an accurate biomarker of IR and MS in diabetic or nor-
mal subjects (26-28).
The study aimed to quantify RBP4 serum standards 
in women with a wide range of body mass index (BMI) 
and glucose tolerance level.
SUBJECTS AND METHODS
Study design
A cross-sectional study was conducted at the Labo-
ratory of Investigation on Metabolism and Diabetes 
(LIMED) – State University of Campinas – Brazil. 
Sample
A total of 139 women were assessed and divided into 
three groups: Group 1 (Lean-control, n = 45), Group 2 
(obese, n = 53), both with normal glucose tolerance, 
and Group 3 (obese with T2DM, n = 41), called G1, 
G2 and G3. T2DM was diagnosed according to the 
American Diabetes Association criteria. 
The inclusion criteria were age over 20 years old, 
premenopause and negative islet autoimmunity. The 
exclusion criteria were use of incretin mimetics, dipep-
tidyl peptidase-4 inhibitors or insulin; significant kid-
ney or liver dysfunction; recent neoplasia (< 5 years); 
and use of oral or injectable corticosteroids for more 
than 14 consecutive days in the last 3 months.
This study was approved by Ethics Committee 
of Faculty of Medical Sciences of State University of 
Campinas, Brazil. All participants provided written in-
formed consent before participation.
Anthropometrical and body composition assessment
The subjects were measured by same examiner, wea-
ring light clothes and no shoes. Height was determined 
using a stadiometer fixed to the wall and weight was 
measured on an electronic digital scale positioned on 
a flat surface. BMI was calculated. Sagittal abdominal 
diameter (SAD) was measured nearest to 0.1 cm af-
ter a normal expiration while subjects were in supine 
position with their knees slightly bent on a firm exa-
mination table. Measurement was taken at umbilicus 
level using the Holtain-Kahn Abdominal Caliper™, a 
portable sliding-beam caliper. Waist circumference was 
measured at standing position by a measuring tape at 
the umbilicus level after a normal expiration without 
clothing present in measurement area. Amounts of 
body fat and fat-free mass were determined using a 
bioimpedance analyzer (model BIA 310) according to 
manufacturer’s protocol (31).
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Assays
Plasma glucose levels were promptly measured in fas-
ting state using a glucose analyzer (YSI 2700; YSI Life 
Sciences, Yellow Spring, OH, USA) with a CV of 2%. 
Glycated hemoglobin was measured with high-perfor-
mance liquid chromatography (HPLC). Plasma insulin 
was analyzed using an automated two-site chemilu-
minescent immunometric assay (Immulite 1000 Sys-
tem; Siemens Health Diagnostics, USA). Intra-assay 
and inter-assay variation coefficients were 5.2-6.4% 
and 5.9-8.0%. Total cholesterol, HDL cholesterol, tri-
glycerides, were measured by enzymatic colorimetric 
method. LDL cholesterol levels were calculated using 
Friedewald method. RBP4 was measured in duplicate 
by ELISA (Phoenix Pharmaceuticals, Inc.). For statis-
tical analysis we considered the mean of two values  ob-
tained. Variation coefficients intra and inter-assay were 
4.5% and 7%, respectively.
Insulin resistance assessment
Insulin resistance was measured using HOMA-IR (Ho-
meostasis Model Assessment – Insulin Resistance) (Fi-
gure 1): 
(BMI and body fat percentage), patients within G3 
had larger waist circumferences and larger SAD than 
those within G2 (p < 0.001), indicating increased 
central fat distribution. As expected, G3 presented 
elevated levels of glycated hemoglobin and fasting 
glucose compared to G1 and G2. Fasting insulin was 
similar among G2 and G3, and augmented compared 
to G1 (p < 0.001). HOMA-IR presented increased 
levels across three study groups, G1 < G2 < G3 (p < 
0.001). Levels of total cholesterol and LDL-choleste-
rol, did not differ among groups, however, levels of 
HDL-cholesterol were augmented and levels of tri-
glycerides were diminished in G1 and G2 compared 
to G3 (p < 0.05) (Table 1). In G3, RBP4 levels were 
lower when compared to G1 (p < 0.05) and similar to 
G2 (Figure 2).
In G1, serum RBP4 correlated positively with BMI 
(r = 0.253), glycated hemoglobin (r = 0.378) and 
fasting insulin (r = 0.336) (p < 0.05); in G2, serum 
RBP4 correlated positively with glycated hemoglobin 
(r = 0.489; p < 0.01) and in G3 serum RBP4 corre-
lated positively with glycated hemoglobin (r = 0.330; 
p < 0.05), fasting glucose (r = 0.463), HOMA-IR (r = 
0.481), (p < 0.01) (Figure 3C). 
DISCUSSION
The main finds of present study were: 1) Serum RBP4 
levels were diminished in obese patients with T2DM 
(G3), compared to patients without T2DM (G2) and 
controls (G1). The last two groups had statistically 
equal results; 2) BMI was positively correlated with 
RBP4 levels in G1, although anthropometric indicators 
of central fat accumulation (waist circumference and 
SAD) did not correlate with RBP4; 3) Glycated hemo-
globin was consistently positive correlated with RBP4 
levels in all studied groups; 4) RBP4 levels correlated 
with HOMA-IR in G3, demonstrating that this adi-
pokine figures as a marker of IR in patients with obesity 
and T2DM.
1) Serum RBP4 levels were diminished in obese pa-
tients with T2DM (G3) compared to patients without 
T2DM (G2), and without T2DM and obesity (G1). 
There seems to be a number of factors interfering 
with correlations and that should be considered when 
interpreting results. Furthermore, genetic differences 
in profile of studied populations, relationships among 
gender and age, have an important role in interpreta-
tion and comparison of data obtained (21).
Figure 1. HOMA-IR formula.
HOMA-IR = 
Fasting insulin (mU/L) x Fasting glucose (mmoI/L)
22,5
Statistical analysis 
Statistical analysis were performed using SPSS 20.0 
(Chicago, IL, USA). In descriptive analysis, continuous 
variables were described using measures of central ten-
dency and dispersion. Kolmogorov-Smirnov test was 
used to assess normality of distribution of variables. 
The comparison among three study groups (G1, G2 
and G3) was performed applying Kruskal Wallis test. 
In situations where there was a statistically significant 
difference was used post-hoc Bonferroni test to identify 
which groups differed. Correlations among study varia-
ble RBP4 with other anthropometric parameters, body 
composition and metabolism were analyzed by Spear-
man correlation test. The level of significance as a basis 
for decision was less than 5% (p < 0.05).
RESULTS
Although all the women assessed were in menacme 
period, G1 was slightly younger than G3 (p < 0.001). 
Interestingly, even with the same grade of obesity 
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Note: values  in the same row and subtable who do not share the same subscript are significantly different at p < 0.05 (Bonferroni test).

















































0 5 10 15 20 25
HOMA-IR
0 2 4 6 8 10



















Figure 3. Levels of RBP4 in three groups. a and b represent groups that 
differed statistically at p < 0.05 (Bonferroni test).
* Correlation is significant at p < 0.05 (two-tailed); ** Correlation is 
significant at p < 0.01 (two-tailed).
RBP4 levels in normal, obese and diabetic women
G1 and G3 differed significantly in age, which prob-
ably reflects in levels of RBP4. There was a positive cor-
relation (p < 0.05) among age and levels of RBP4 in 
G2. No gender difference was analyzed since the study 
included only women in menacme period.
2) Although BMI was positively correlated with 
RBP4 levels in G1, anthropometric indicators of cen-
tral fat accumulation (waist circumference and SAD) 
did not correlate with RBP4. 
Evaluating correlation among RBP4 x BMI and 
RBP4 x % Body fat, is noted that body fat amount ap-
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3) Glycated hemoglobin was consistently correlated 
with RBP4 levels in all studied groups. 
Our findings show that glycated hemoglobin le vels 
were significantly correlated in all groups with levels 
of RBP4. While when we evaluated fasting glucose 
there was no such trend in G1 and G2, groups without 
T2DM.
In G3, whose fasting glucose is greater than in 
other groups, there was a strong positive correlation 
following the tendency of increased glycated hemoglo-
bin levels. This finding, in particular, confirms existing 
literature (7), higher was the level of RBP4 in obese 
diabetic more correlated with levels of fasting glucose 
and glycated hemoglobin, perhaps because RBP4 gene 
encoder is located very near genes linked to obesity and 
T2DM.
4) RBP4 levels correlated with HOMA-IR in G3, 
demonstrating this adipokine figures as a marker of IR 
in patients with obesity and T2DM. 
The RBP4 is an adipokine consistently associated 
with IR in animal models (knockout only for GLUT4 
receptor in adipose tissue) and was also considered a 
promising adipokine in humans, possibly linking adi-
posity, IR, T2DM and certain components of the meta-
bolic syndrome (11,31).
Retinol binding protein 4 seems to be involved in 
early phases of IR development and other metabolic 
syndrome components. Therefore, longitudinal stu-
dies are needed to investigate how change will occur 
in RBP4 levels especially in children and adolescents 
predisposed to these conditions.
The study of RBP4 must be extensive, due to va-
rious sources and polymorphisms in genes encoding 
this protein and genes encoding one of its receptors.
In this study we found a positive correlation among 
RBP4 levels and some biochemical parameters. Ho-
wever, in several clinical studies, associations and/or 
causality of changes in the expression of RBP4 were 
not demonstrated (21).
Limitations of study 
Methodological differences in sample collection and 
determination of RBP4 levels should be considered. 
Studies showed there is a variation in protein quantifi-
cation according to used methods (21).
Other interfering factors, such as levels of retinol, 
iron and even renal function appear to be important 
and should be investigated in future studies (18).
Deeper studies, using other research methods with 
human adipocytes, are necessary to reveal how secre-
tion and regulation of RBP4 expression works and its 
self-paracrine effect. 
Differences in results of this study regarding others 
can also be caused by different methods of RBP4 quan-
tification. 
CONCLUSIONS
In our study, unexpectedly, the levels of RBP4 were re-
duced in patients with both obesity and T2DM com-
pared to patients without obesity and T2DM. On the 
other hand, consistently thorough the three groups, 
RPB-4 was positively and strongly correlated with gly-
cated hemoglobin and with IR in the G3. 
This apparent discrepancy, also demonstrated by 
other studies, may be explained by the interference of 
other factors (assay technique, genetic variations, levels 
of retinol, iron and even renal function), or metabolic 
control degree.
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